- Home
- SLDB
as 03-31-2025 4:00pm EST
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 366.2M | IPO Year: | 2018 |
| Target Price: | $18.10 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.88 - $13.47 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 717.65% |
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kahn Clare | SLDB | Director | Mar 11 '25 | Buy | $5.34 | 1,860 | $9,924.40 | 2,960 | |
| PERCEPTIVE ADVISORS LLC | SLDB | Director10% Owner | Feb 19 '25 | Buy | $4.03 | 5,000,000 | $20,150,000.00 | 11,833,539 | |
| Bain Capital Life Sciences Investors, LLC | SLDB | 10% Owner | Feb 19 '25 | Buy | $4.03 | 1,000,000 | $4,030,000.00 | 5,034,582 | |
| Adage Capital Management, L.P. | SLDB | 10% Owner | Feb 18 '25 | Buy | $7.56 | 252,545 | $1,909,240.20 | 4,248,084 | |
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Feb 13 '25 | Sell | $3.96 | 3,079 | $12,192.84 | 19,281 | |
| Brooks Gabriel | SLDB | Chief Medical Officer | Feb 13 '25 | Sell | $3.96 | 3,256 | $12,893.76 | 22,812 | |
| Ganot Ilan | SLDB | Director | Feb 13 '25 | Sell | $3.96 | 1,711 | $6,775.56 | 14,839 | |
| Howton David T | SLDB | Chief Operating Officer | Feb 13 '25 | Sell | $3.96 | 5,561 | $22,021.56 | 24,789 | |
| Tan Kevin | SLDB | CFO & Treasurer | Feb 13 '25 | Sell | $3.96 | 3,164 | $12,529.44 | 32,250 | |
| Herzich Paul | SLDB | Chief Technology Officer | Feb 13 '25 | Sell | $3.96 | 2,688 | $10,644.48 | 18,388 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
Insider Monkey
17 days ago
Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month
GlobeNewswire
19 days ago
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Zacks
24 days ago
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
Zacks
24 days ago
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
GlobeNewswire
25 days ago
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
a month ago
Solid Biosciences to Participate at Upcoming Investor Conferences
Insider Monkey
a month ago
Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently?
GlobeNewswire
a month ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare SLDB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.